Inhibition of PKCα has decreased the invasion of urinary bladder carcinoma [30], colon carcinoma [31], renal cell carcinoma [32], breast carcinoma [33], multiple myeloma [34], glioma [35], breast cancer [36] and endometrial cancer cells [37]. This evidence concerns the gene PRKCA and breast carcinoma.